Continued investment in R&D at a fixed percentage of sales
First written in FY2016. 31 of 33 entries say "Restated". Latest entry: 2026-08-07.
The whole theme swung hardest in 2020: 1 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Advanced".
- FY2026-H1RestatedAnnual report
「The Group's total R&D expenses for the interim consolidated accounting period were ¥1,421 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The absence of material changes in R&D activities was reaffirmed, and R&D expenses for the interim consolidated accounting period were reported as ¥1,421 million. - FY2025-H1RestatedAnnual report
「The Group's total R&D expenses for the interim consolidated accounting period were ¥1,494 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The absence of material changes in the status of R&D activities was reaffirmed, and R&D expenses for the interim consolidated accounting period were reported as ¥1,494 million. - FY2024RestatedAnnual report
「The Group conducts R&D across a range of fields to respond to an increasingly information-oriented society, and invests in R&D with a certain percentage of net sales as a guideline. Total R&D-related expenses for the fiscal year were ¥2,791 million.」
The policy of investing a certain percentage of net sales in R&D was maintained, and R&D-related expenses were ¥2,791 million. - FY2024-Q3RestatedAnnual report
「The Group's total R&D expenses for the cumulative third quarter were ¥2,137 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The absence of material changes in the status of R&D activities was reaffirmed, and R&D expenses for the cumulative third quarter were reported as ¥2,137 million. - FY2024-Q2RestatedAnnual report
「The Group's total R&D expenses for the cumulative second quarter were ¥1,421 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
The absence of material changes in the status of R&D activities was reaffirmed, and R&D expenses were reported as ¥1,421 million. - FY2024-Q1RestatedAnnual report
「The Group's total R&D expenses for the cumulative first quarter were ¥719 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
The absence of material changes in the status of R&D activities was reaffirmed, and R&D expenses for the quarter were reported as ¥719 million. - FY2023-Q3RestatedAnnual report
「The Group's total R&D expenses for the cumulative third quarter were ¥2,170 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
No material changes were reported in R&D activities, and the policy of continuing R&D investment was reaffirmed. - FY2023-Q2RestatedAnnual report
「The Group's total R&D expenses for the cumulative second quarter were ¥1,431 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
No material changes were reported in R&D activities, and R&D expenses for the cumulative second quarter were reported as ¥1,431 million. - FY2023-Q1RestatedAnnual report
「The Group's total R&D expenses for the cumulative first quarter were ¥692 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
No material changes were reported in R&D activities, and the policy of continuing R&D investment was reaffirmed. R&D expenses were ¥692 million. - FY2022-Q2RestatedAnnual report
「The Group's total R&D expenses for the cumulative second quarter were ¥1,296 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
No material changes were reported in the status of R&D activities, and the policy of continuing R&D investment was reaffirmed. R&D expenses were ¥1,296 million. - FY2022-Q1RestatedAnnual report
「The Group's total R&D expenses for the cumulative first quarter were ¥648 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
The absence of material changes in the status of R&D activities was reaffirmed, and R&D expenses for the quarter were reported as ¥648 million. - FY2021RestatedAnnual report
「The Group conducts R&D across a range of fields to respond to an increasingly information-oriented society, and invests in R&D with a certain percentage of net sales as a guideline. Total R&D-related expenses for the fiscal year were ¥2,410 million.」
The policy of investing a certain percentage of net sales in R&D was maintained, and R&D-related expenses for the year were ¥2,410 million. - FY2021-Q3RestatedAnnual report
「The Group's total R&D expenses for the cumulative third quarter were ¥1,803 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
No material changes were reported in R&D activities, and the policy of continuing R&D investment was reaffirmed. R&D expenses were ¥1,803 million. - FY2021-Q2RestatedAnnual report
「The Group's total R&D expenses for the cumulative second quarter were ¥1,190 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
R&D expenses were ¥1,190 million, and no material changes were reported in the status of R&D activities. No change in the policy of investing a certain percentage of net sales in R&D was reported. - FY2021-Q1RestatedAnnual report
「The Group's total R&D expenses for the cumulative first quarter were ¥634 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
No material changes were reported in the status of R&D activities, and the policy of continuing investment was reaffirmed. R&D expenses were ¥634 million. - FY2020RestatedAnnual report
「The Group conducts R&D across a range of fields to respond to an increasingly information-oriented society, and invests in R&D with a certain percentage of net sales as a guideline. Total R&D-related expenses for the fiscal year were ¥2,675 million.」
The policy of investing a certain percentage of net sales in R&D was maintained, and R&D-related expenses for the year were ¥2,675 million. - FY2020-Q3RestatedAnnual report
「The Group's total R&D expenses for the cumulative third quarter were ¥2,015 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
No material changes were reported in the status of R&D activities, and the policy of continuing R&D investment was reaffirmed. R&D expenses were ¥2,015 million. - FY2020-Q2RestatedAnnual report
「The Group's total R&D expenses for the cumulative second quarter were ¥1,352 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
No material changes were reported in the status of R&D activities, and the policy of continuing R&D investment was reaffirmed. R&D expenses were ¥1,352 million. - FY2020-Q1RestatedAnnual report
「The Group's total R&D expenses for the cumulative first quarter were ¥673 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
No material changes were reported in the status of R&D activities, and the policy of continuing R&D investment was reaffirmed. R&D expenses were ¥673 million. - FY2019RestatedAnnual report
「The Group conducts R&D across a range of fields to respond to an increasingly information-oriented society, and invests in R&D with a certain percentage of net sales as a guideline. Total R&D-related expenses for the fiscal year were ¥2,717 million.」
The policy of investing a certain percentage of net sales in R&D was maintained, and R&D-related expenses for the year were ¥2,717 million. - FY2019-Q3RestatedAnnual report
「The Group's total R&D expenses for the cumulative third quarter were ¥2,031 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
No material changes were reported in R&D activities, and the policy of continuing investment was reaffirmed. R&D expenses were ¥2,031 million. - FY2019-Q2RestatedAnnual report
「The Group's total R&D expenses for the cumulative second quarter were ¥1,331 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
No material changes were reported in R&D activities, and the policy of continuing investment was reaffirmed. R&D expenses were ¥1,331 million. - FY2019-Q1RestatedAnnual report
「The Group's total R&D expenses for the cumulative first quarter were ¥658 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
No material changes were reported in R&D activities, and the policy of continuing investment was reaffirmed. R&D expenses were ¥658 million. - FY2018-Q3RestatedAnnual report
「The Group's total R&D expenses for the cumulative third quarter were ¥1,974 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
R&D expenses were ¥1,974 million, and it was stated that there were no material changes in the status of R&D activities. - FY2018-Q2RestatedAnnual report
「The Group's total R&D expenses for the cumulative second quarter were ¥1,307 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
No material changes were reported in R&D activities, and the policy of continuing investment was reaffirmed. R&D expenses were ¥1,307 million. - FY2018-Q1RestatedAnnual report
「The Group's total R&D expenses for the cumulative first quarter were ¥635 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
No material changes were reported in R&D activities, and the policy of continuing investment was reaffirmed. - FY2017RestatedAnnual report
「The Group conducts R&D across a range of fields to respond to an increasingly information-oriented society, and invests in R&D with a certain percentage of net sales as a guideline. Total R&D-related expenses for the fiscal year were ¥2,516 million.」
The policy of investing a certain percentage of net sales in R&D was maintained, and R&D-related expenses for the year were reported as ¥2,516 million. - FY2017-Q3RestatedAnnual report
「The Group's total R&D expenses for the cumulative third quarter were ¥1,876 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
R&D expenses were ¥1,876 million, and no material changes were reported in the status of R&D activities. - FY2017-Q2RestatedAnnual report
「The Group's research and development expenditure for the cumulative second quarter was ¥1,241 million. There were no significant changes in the status of the Group's research and development activities during the cumulative second quarter.」
R&D expenses were ¥1,241 million, and no material changes were reported in the status of R&D activities. - FY2017-Q1RestatedAnnual report
「The Group's research and development expenditure for the cumulative first quarter was ¥613 million. There were no significant changes in the status of the Group's research and development activities during the cumulative first quarter.」
Quarterly research and development expenditure was ¥613 million, and the company states that there were no significant changes in the status of its research and development activities. - FY2016First statedAnnual report
「The Group invests in research and development with the aim of allocating a certain proportion of sales to such investment.」
Although no specific proportion is stated, this indicates a policy of linking research and development investment to sales.